- United States
- /
- Biotech
- /
- NasdaqGM:MNOV
US Penny Stocks To Watch In December 2024
Reviewed by Simply Wall St
As the U.S. stock market navigates a volatile landscape marked by benign inflation data and fluctuating interest rate expectations, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with speculative ventures, can offer unique value when supported by strong financials and growth potential. This article will explore three penny stocks that stand out for their robust financial health, presenting intriguing possibilities for investors seeking under-the-radar companies with long-term promise.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Inter & Co (NasdaqGS:INTR) | $4.04 | $1.73B | ★★★★☆☆ |
BAB (OTCPK:BABB) | $0.893925 | $6.49M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $105.8M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.76 | $84.32M | ★★★★★★ |
Pangaea Logistics Solutions (NasdaqCM:PANL) | $4.99 | $236.39M | ★★★★★☆ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) | $1.44 | $47.69M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $0.95 | $17.08M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.82 | $71.95M | ★★★★★☆ |
Safe Bulkers (NYSE:SB) | $3.50 | $382.26M | ★★★★☆☆ |
Click here to see the full list of 742 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Senmiao Technology (NasdaqCM:AIHS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Senmiao Technology Limited operates in the automobile transaction and related services sector in the People's Republic of China, with a market cap of $9.26 million.
Operations: The company generates revenue primarily from its automobile transactions and related services segment, totaling $3.57 million.
Market Cap: $9.26M
Senmiao Technology Limited, with a market cap of US$9.26 million, faces challenges typical of penny stocks. Its revenue from automobile transactions was US$3.57 million, but recent earnings show a decline in sales to US$0.75 million for the second quarter compared to the previous year. The company is unprofitable, with net losses increasing over five years at 0.4% annually and shareholders experiencing dilution recently as shares outstanding grew by 9.9%. Despite having more cash than debt and an experienced management team, its short-term liabilities exceed assets by US$3.4 million, indicating financial strain ahead.
- Jump into the full analysis health report here for a deeper understanding of Senmiao Technology.
- Learn about Senmiao Technology's historical performance here.
MediciNova (NasdaqGM:MNOV)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel and small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $105.45 million.
Operations: MediciNova, Inc. has not reported any revenue segments.
Market Cap: $105.45M
MediciNova, Inc., with a market cap of US$105.45 million, is a pre-revenue biopharmaceutical company facing challenges common to penny stocks. Despite being debt-free and having sufficient cash runway for over three years, the company remains unprofitable with a net loss of US$2.85 million in the recent quarter. Recent developments include receiving a Notice of Allowance from the USPTO for MN-001 (Tipelukast), potentially enhancing its intellectual property portfolio until 2042. Additionally, MediciNova collaborates on an NIH-funded trial for ALS treatment using MN-166 (ibudilast), reflecting its ongoing commitment to advancing therapeutic options in unmet medical needs areas.
- Click to explore a detailed breakdown of our findings in MediciNova's financial health report.
- Understand MediciNova's earnings outlook by examining our growth report.
FansUnite Entertainment (OTCPK:FUNF.F)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: FansUnite Entertainment Inc. is a sports and entertainment company with a market cap of $71,911.
Operations: FansUnite Entertainment Inc. does not have any reported revenue segments at this time.
Market Cap: $71.91k
FansUnite Entertainment Inc., with a market cap of CA$71,911, is a pre-revenue sports and entertainment company. Despite being unprofitable with negative return on equity, it reported improved earnings in the recent quarter, achieving a net income of CAD 8.4 million compared to last year's loss. The company benefits from no long-term liabilities and sufficient cash runway for over three years due to positive free cash flow growth. Its share price has been highly volatile recently, yet it trades significantly below estimated fair value. The board and management team are experienced with an average tenure of 4.3 years.
- Dive into the specifics of FansUnite Entertainment here with our thorough balance sheet health report.
- Examine FansUnite Entertainment's past performance report to understand how it has performed in prior years.
Key Takeaways
- Jump into our full catalog of 742 US Penny Stocks here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:MNOV
MediciNova
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
Flawless balance sheet slight.